4-cyclopropyl-thiazole-2-carbonyl chloride | 1180496-28-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-cyclopropyl-thiazole-2-carbonyl chloride
• 英文别名: 4-cyclopropyl-1,3-thiazole-2-carbonyl chloride
• CAS: 1180496-28-9
• 化学式: C₇H₆ClNOS
• 分子量: 187.65
• InChiKey: PTCMPZCXGSCXLO-UHFFFAOYSA-N

物化性质

• 沸点：
  317.6±35.0 °C(Predicted)
• 密度：
  1.482±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  58.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-cyclopropyl-thiazole-2-carbonyl chloride 在 吡啶 、 盐酸 、 potassium tert-butylate 、 sodium hydride 、 三乙胺 、 potassium hydroxide 、 三氯氧磷 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 二氯甲烷 、 二甲基亚砜 为溶剂， 反应 7.0h， 生成
  参考文献：
  名称：

  Synthesis and antiviral activity of novel HCV NS3 protease inhibitors with P4 capping groups

  摘要：

  We have synthesized and evaluated a series of novel HCV NS3 protease inhibitors with various P4 capping groups, which include urea, carbamate, methoxy-carboxamide, cyclic carbamate and amide, pyruvic amide, oxamate, oxalamide and cyanoguanidine. Most of these compounds are remarkably potent, exhibiting single-digit to sub-nanomolar activity in the enzyme assay and cell-based replicon assay. Selected compounds were also evaluated in the protease-inhibitor-resistant mutant transient replicon assay, and they were found to show quite different potency profiles against a panel of HCV protease-inhibitor-resistant mutants. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.10.075
• 作为产物：
  描述：

  2-溴-1-环丙基乙酮 在 草酰氯 、 sodium hydroxide 作用下， 以 甲醇 、 二氯甲烷 、 水 为溶剂， 反应 2.0h， 生成 4-cyclopropyl-thiazole-2-carbonyl chloride
  参考文献：
  名称：

  Synthesis and antiviral activity of novel HCV NS3 protease inhibitors with P4 capping groups

  摘要：

  We have synthesized and evaluated a series of novel HCV NS3 protease inhibitors with various P4 capping groups, which include urea, carbamate, methoxy-carboxamide, cyclic carbamate and amide, pyruvic amide, oxamate, oxalamide and cyanoguanidine. Most of these compounds are remarkably potent, exhibiting single-digit to sub-nanomolar activity in the enzyme assay and cell-based replicon assay. Selected compounds were also evaluated in the protease-inhibitor-resistant mutant transient replicon assay, and they were found to show quite different potency profiles against a panel of HCV protease-inhibitor-resistant mutants. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.10.075

文献信息

• [EN] MACROCYCLIC SERINE PROTEASE INHIBITORS USEFUL AGAINST VIRAL INFECTIONS, PARTICULARLY HCV<br/>[FR] INHIBITEURS MACROCYCLIQUES DE LA SÉRINE PROTÉASE MACROCYCLIQUE UTILES CONTRE LES INFECTIONS VIRALES, EN PARTICULIER LE VIRUS DE L’HÉPATITE C
  申请人：IDENIX PHARMACEUTICALS INC

  公开号：WO2011017389A1

  公开（公告）日：2011-02-10

  Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula (Ia) or (Ib), pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.

  本文提供了大环丝氨酸蛋白酶抑制剂化合物，例如，化学式（Ia）或（Ib）所示的化合物，包括这些化合物的药物组合物，以及其制备方法。还提供了它们用于治疗宿主中HCV感染的方法。
• MACROCYCLIC SERINE PROTEASE INHIBITORS
  申请人：Parsy Christophe Claude

  公开号：US20100260710A1

  公开（公告）日：2010-10-14

  Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula Ia or Ib, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.

  本文提供了大环丝氨酸蛋白酶抑制剂化合物，例如，Ia或Ib式的化合物，包括这些化合物的药物组合物，以及其制备方法。还提供了它们用于治疗宿主HCV感染的方法。
• COMPOUNDS
  申请人：COOPER JOEL

  公开号：US20100196321A1

  公开（公告）日：2010-08-05

  The present invention features compounds of Formula (I) and (Ia), pharmaceutical compositions and use in the treatment of viral disease:

  这项发明涉及Formula (I)和(Ia)的化合物，药物组合物以及在治疗病毒性疾病中的应用。
• Macrocyclic serine protease inhibitors
  申请人：Parsy Christophe Claude

  公开号：US08377962B2

  公开（公告）日：2013-02-19

  Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula Ia or Ib, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.

  本文提供了大环丝氨酸蛋白酶抑制剂化合物，例如Ia或Ib式的化合物，包括含有该化合物的制药组合物以及其制备方法。还提供了它们用于治疗宿主中需要治疗HCV感染的方法。
• [EN] MACROCYCLIC SERINE PROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE SÉRINE PROTÉASE MACROCYCLIQUES
  申请人：IDENIX PHARAMACEUTICALS INC

  公开号：WO2009099596A2

  公开（公告）日：2009-08-13

  Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula (I), pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.